Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.65 BRL | +10.27% | +14.78% | -62.06% |
Jun. 14 | Brazil's Dasa, Amil to combine hospital businesses | RE |
Jun. 10 | Brazil's Dasa, Amil in advanced talks to combine hospital businesses | RE |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.84 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- With an expected P/E ratio at 68.44 and 6.99 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-62.06% | 500M | C+ | ||
+19.84% | 84.94B | C+ | ||
-25.24% | 74.07B | B- | ||
-1.34% | 26.15B | C+ | ||
+4.56% | 18.03B | A- | ||
-9.29% | 17.38B | B | ||
+4.52% | 16.01B | A- | ||
+78.16% | 13.7B | C- | ||
+77.84% | 13.13B | C+ | ||
-26.14% | 12.74B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DASA3 Stock
- Ratings Diagnosticos da América S.A.